At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
For more than 40 years, Option Care has been shaping the home infusion services in...
For more than 40 years, Option Care has been sh...
Atreca is a biotechnology company developing novel therapeutics drawn from human i...
Atreca is a biotechnology company developing no...
Applied Science Products operates Advanced Plasma Products, Inc., a science and en...
Applied Science Products operates Advanced Plas...
Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...
Headquartered in Waltham, Massachusetts, we dev...
Join the National Investor Network and get the latest information with your interests in mind.